Report: Preliminary injunction to block ESI-Medco merger denied
PITTSBURGH — The U.S. District Court for the Western District of Pennsylvania on Wednesday denied a preliminary injunction filed by pharmacy trade groups in an effort to block the merger between pharmacy benefit managers Express Scripts and Medco.
According to a Reuters report, U.S. District Judge Cathy Bissoon, who said earlier this month she would rule "later" on whether to block or allow a merger between the PBMs, declined to issue the preliminary injunction, which would require ESI to divest or separate Medco. A decision regarding a permanent injunction has not yet been made.
As previously reported, the Federal Trade Commission approved the deal despite efforts from the National Association of Chain Drug Stores, the National Community Pharmacists Association and several other retail pharmacy companies to block the merger. Consumer groups, including the Consumer Federation of America, the National Consumers League, the National Legislative Association on Prescription Drug Prices and U.S. PIRG (a federation of 28 nonprofit, nonpartisan state Public Interest Research Groups), filed an amici curiae on behalf of retail pharmacy plaintiffs in their suit to dismantle the ESI-Medco merger.
Reports: GSK calls $2.6 billion offer for Human Genome Sciences ‘full and fair’
NEW YORK — GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.
Reuters reported that GSK’s $13-per-share, $2.6 billion offer for HGS would give the former full control of Benlysta (belimumab), the first new drug approved by the Food and Drug Administration for lupus in more than half a century. The two companies developed the drug together under a partnership, and the drug received approval in March 2011.
On Friday, HGS confirmed that GSK had offered to buy it, but concluded that the offer "does not reflect the value inherent in HGS."
The companies’ partnership also includes darapladib, a cardiovascular disease drug currently in phase-3 development; and albiglutide, also in phase-3 development, for Type 2 diabetes.
RxMedic opens new headquarters
RALEIGH, N.C. — A company that manufactures pharmacy dispensing machines has moved into a new headquarters.
RxMedic Systems announced Wednesday the opening of the new headquarters in Wake Forest, N.C., a suburb of Raleigh. The company said expansion of product lines created the need to move into a new location. "With our recent growth, we had just outgrown our previous location," VP David Williams said. "Now, we have much more space for both product development and manufacturing."